Expression and its Clinical Prognosis of hMSH2 in Bladder Urothelial Carcinoma
ZHANG Chun-ting,LU Rong,XU Yong
Department of Urology, Jinhua City People’s Hospital, Jinhua (321000), China
Abstract:
Objective To investigate the expression of hMSH2 in bladder urothelial carcinoma and its clinical prognosis. Methods SP immunohistochemistry was used to detect expression of hMSH2 in 72 cases of bladder urothelial carcinoma and 49 cases of bladder normal tissues. The results and the clinical data of bladder urothelial carcinoma were analyzed. Kaplan-Meier survival was used to analyze the relationship between hMSH2 and 5-year recurrence of bladder urothelial carcinoma. Results The positive rate of hMSH2 protein expression of bladder urothelial carcinoma and normal bladder tissue was respectively 34.72%(25/72) and 91.84%(45/49),hMSH2 protein expression positive rate were 44.4% (20/45) at level Ⅰ , 18.51% at level Ⅱ - Ⅲ (5/27), the difference is significant between groups (P < 0.05). The positive expression rates of hMSH2 protein in Tis ~ T1 and T2 ~ T4 were respectively 43.48%(20/46) and 19.23%(5/26), the difference was significant (P <0.05).Kaplan-Meier survival analysis showed that the recurrence rate of hMSH2 expression and negative hMSH2 expression were respectively 19.35%(6/31) and 46.34%(19/41) in the 5-year follow-up, the difference was significant (P <0.05). Conclusion The decreased expression of hMSH2 protein in bladder urothelial carcinoma is related to its differentiation, clinical stage and 5-year recurrence. hMSH2 may be involved in the evolution and progression of bladder urothelial carcinoma.
